Evicenter
Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer
Manufacturer
Novartis Pharmaceuticals Corporation
Prescribing information
Kisqali (opens in a new tab)
Questions
57
Last updated

All questions

Specific populations: Kisqali (ribociclib) in HR-positive HER2-negative advanced or metastatic breast cancer

3 questions · 3 sources

Specific populations

How does Kisqali safety compare in older patients with metastatic breast cancer?

Applies to Patients with HR-positive, HER2-negative advanced or metastatic breast cancer in pooled analyses of MONALEESA-2, MONALEESA-3, and MONALEESA-7

Note: The discontinuation rates by age are from an exploratory, pooled, post hoc analysis of first-line patients in MONALEESA-2, MONALEESA-3, and MONALEESA-7 on the data across age groups page of the Kisqali HCP site.

Can men with metastatic breast cancer take Kisqali?

Applies to Men with HR-positive, HER2-negative advanced or metastatic breast cancer

Note: COMPLEEMENT-1 was a single-arm study; the Prescribing Information reports its overall response rate and duration of response in a table.

What is the Kisqali dose for liver (hepatic) impairment?